Virginia Commonwealth University

The Children's Hospital of Philadelphia

Jurgen Venitz

Martin K Safo

Yan Zhang

Richmond E Danso-Danquah

Mohini Ghatge

Tanvi Deshpande

Kevin R Ward

Martin J Mangino

Osheiza Abdulmalik

Guoyan Xu

Richmond Danso-Danqua

Piyusha Pradeep Pagare

Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

Aromatic aldehydes with sustained and enhanced in vitro and in vivo pharmacologic activity to treat sickle cell disease

The invention provides new aromatic aldehyde compounds that have greater potency in increasing the affinity of Hb for oxygen, greater potency for preventing sickling, and additional pharmacologic properties that ameliorate other symptoms of SCD. The invention further provides methods for treating SCD by providing a subject having SCD with a compound according to the invention.

Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease

Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.

Allosteric hemoglobin modifiers with nitric oxide releasing moiety

Growing community of inventors

Richmond, VA, United States of America

Jurgen Venitz